Skip to main content

Publications

What type of publication do you want to show?

2022

Are UK pharmacists ready for consultant-level practice? A cross-sectional survey of self-assessed development needs

Forsyth, P., Radley, A., Marra, F., Roberts, D., Sehrawat, M., Aiello, M., . . . Roberts, S. (2022). Are UK pharmacists ready for consultant-level practice? A cross-sectional survey of self-assessed development needs. INTERNATIONAL JOURNAL OF PHARMACY PRACTICE, 30(6), 559-566. doi:10.1093/ijpp/riac070

DOI
10.1093/ijpp/riac070
Journal article

Safe co-administration of direct-acting antivirals and direct oral anticoagulants among patients with hepatitis C virus infection: An international multicenter retrospective cohort study

McDaniel, K., Utz, A. E., Akbashev, M., Fuller, K. G., Boyle, A., Davidson, K., . . . Miller, L. S. (2022). Safe co-administration of direct-acting antivirals and direct oral anticoagulants among patients with hepatitis C virus infection: An international multicenter retrospective cohort study. JOURNAL OF VIRAL HEPATITIS, 29(12), 1073-1078. doi:10.1111/jvh.13750

DOI
10.1111/jvh.13750
Journal article

Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions

Marzolini, C., Kuritzkes, D. R., Marra, F., Boyle, A., Gibbons, S., Flexner, C., . . . Khoo, S. (2022). Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions. ANNALS OF INTERNAL MEDICINE, 175(5), 744-+. doi:10.7326/M22-0281

DOI
10.7326/M22-0281
Journal article

2021

2020

REAL-WORLD OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION AND SUBSTANCE ABUSE DISORDERS TREATED WITH GLECAPREVIR/PIBRENTASVIR FOR 8 WEEKS: A POOLED ANALYSIS OF MULTINATIONAL POST-MARKETING OBSERVATIONAL STUDIES

Rizzardini, G., Gschwantler, M., Bourgeois, S., Mullhaupt, B., Mazur, W., Bondin, M., . . . Foucher, J. (2020). REAL-WORLD OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION AND SUBSTANCE ABUSE DISORDERS TREATED WITH GLECAPREVIR/PIBRENTASVIR FOR 8 WEEKS: A POOLED ANALYSIS OF MULTINATIONAL POST-MARKETING OBSERVATIONAL STUDIES. In HEPATOLOGY Vol. 72 (pp. 568A-569A). Retrieved from https://www.webofscience.com/

Conference Paper

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naive Patients with Compensated Cirrhosis (vol 37, pg 4033, 2020)

Lampertico, P., Mauss, S., Persico, M., Barclay, S. T., Marx, S., Lohmann, K., . . . Flamm, S. (2020). Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naive Patients with Compensated Cirrhosis (vol 37, pg 4033, 2020). ADVANCES IN THERAPY, 37(11), 4755-4756. doi:10.1007/s12325-020-01482-z

DOI
10.1007/s12325-020-01482-z
Journal article

2019

Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in hepatitis C virus genotype 1-and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries

Ferenci, P., Bourgeois, S., Buggisch, P., Norris, S., Curescu, M., Larrey, D., . . . Flisiak, R. (2019). Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in hepatitis C virus genotype 1-and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries. JOURNAL OF VIRAL HEPATITIS, 26(6), 685-696. doi:10.1111/jvh.13080

DOI
10.1111/jvh.13080
Journal article

Drug-drug interactions in HCV therapy: Still relevant for clinical practice?

Schulte, B., Wubbolding, M., Port, K., Manns, M. P., Back, D., Marra, F., . . . zu Siederdissen, C. H. (2019). Drug-drug interactions in HCV therapy: Still relevant for clinical practice?. In JOURNAL OF HEPATOLOGY Vol. 70 (pp. E240). doi:10.1016/S0618-8278(19)30453-0

DOI
10.1016/S0618-8278(19)30453-0
Conference Paper

Drug Interactions in the Treatment of Hepatitis C Virus Infection - still relevant for clinical Practice?

Schulte, B., Wuebbolding, M., Port, K., Back, D., Marra, F., Manns, M. P., . . . zu Siederdissen, C. H. (2019). Drug Interactions in the Treatment of Hepatitis C Virus Infection - still relevant for clinical Practice?. In INTERNIST Vol. 60 (pp. S27). Retrieved from https://www.webofscience.com/

Conference Paper

GLECAPREVIR/PIBRENTASVIR FOR PATIENTS WITH MARKERS OF ADVANCED CIRRHOSIS: OUTCOMES FROM ROUTINE CLINICAL CARE.

Boyle, A., Marra, F., Peters, E., Priest, M., Mcdonald, N., Datta, S., & Barclay, S. T. (2019). GLECAPREVIR/PIBRENTASVIR FOR PATIENTS WITH MARKERS OF ADVANCED CIRRHOSIS: OUTCOMES FROM ROUTINE CLINICAL CARE.. In HEPATOLOGY Vol. 70 (pp. 937A). Retrieved from https://www.webofscience.com/

Conference Paper

USING POINT OF CARE TESTING, SIMPLIFIED ASSESSMENT AND MONITORING AND MULTIDISCIPLINARY INITIATION OF TREATMENT TO ELIMINATE HEPATITIS C IN A COMMUNITY ADDICTIONS CLINIC: RESULTS FROM PHASE 1 OF THE SPRINGBURN MICROELIMINATION PROJECT

Marra, F., Boyle, A., Govender, C., Biggart, L., Sills, L., Ritchie, T., & Barclay, S. T. (2019). USING POINT OF CARE TESTING, SIMPLIFIED ASSESSMENT AND MONITORING AND MULTIDISCIPLINARY INITIATION OF TREATMENT TO ELIMINATE HEPATITIS C IN A COMMUNITY ADDICTIONS CLINIC: RESULTS FROM PHASE 1 OF THE SPRINGBURN MICROELIMINATION PROJECT. In HEPATOLOGY Vol. 70 (pp. 963A). Retrieved from https://www.webofscience.com/

Conference Paper

2018

Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications

Marra, F., zu Siederdissen, C. H., Khoo, S., Back, D., Schlag, M., Ouwerkerk-Mahadevan, S., . . . Cornberg, M. (2018). Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 84(5), 961-971. doi:10.1111/bcp.13519

DOI
10.1111/bcp.13519
Journal article

8 weeks sofosbuvir/velpatasvir in genotype 3 patients with significant fibrosis: Highly effective amongst an OST cohort

Boyle, A., Marra, F., Peters, E., Heydtmann, M., Cairns, H., Datta, S., & Barclay, S. (2018). 8 weeks sofosbuvir/velpatasvir in genotype 3 patients with significant fibrosis: Highly effective amongst an OST cohort. In JOURNAL OF HEPATOLOGY Vol. 68 (pp. S20). doi:10.1016/S0168-8278(18)30259-9

DOI
10.1016/S0168-8278(18)30259-9
Conference Paper

Grazoprevir/elbasvir dosing according to viral load and NS5A resistance: real world confirmation of the efficacy of EASL guidance

Marra, F., Boyle, A., Gunson, R., Bradley, A., Thomson, E., & Barclay, S. (2018). Grazoprevir/elbasvir dosing according to viral load and NS5A resistance: real world confirmation of the efficacy of EASL guidance. In JOURNAL OF HEPATOLOGY Vol. 68 (pp. S287-S288). doi:10.1016/S0168-8278(18)30794-3

DOI
10.1016/S0168-8278(18)30794-3
Conference Paper

Integrated efficacy and safety of glecaprevir/pibrentasvir in patients with psychiatric disorders

Back, D., Belperio, P., Bondin, M., Negro, F., Talal, A., Park, C., . . . Marra, F. (2018). Integrated efficacy and safety of glecaprevir/pibrentasvir in patients with psychiatric disorders. In JOURNAL OF HEPATOLOGY Vol. 68 (pp. S280-S281). doi:10.1016/S0168-8278(18)30778-5

DOI
10.1016/S0168-8278(18)30778-5
Conference Paper

Uniform addition of ribavirin to sofosbuvir/velpatasvir for genotype 3 patients with cirrhosis: real world outcomes

Boyle, A., Marra, F., Reilly, E., Fleming, C., Heydtmann, M., Fox, R., . . . Barclay, S. (2018). Uniform addition of ribavirin to sofosbuvir/velpatasvir for genotype 3 patients with cirrhosis: real world outcomes. In JOURNAL OF HEPATOLOGY Vol. 68 (pp. S256-S257). doi:10.1016/S0168-8278(18)30726-8

DOI
10.1016/S0168-8278(18)30726-8
Conference Paper

Drug-Drug Interaction Potential of Glecaprevir/Pibrentasvir Based on Real-World Use of Co-Medications in Patients with Chronic Hepatitis C Virus Infection: Data from the German Hepatitis C Registry (DHC-R)

Vermehren, J., Boeker, K. H. W., Bondin, M. I., Mauss, S., Pathil, A., Klinker, H., . . . Buggisch, P. (2018). Drug-Drug Interaction Potential of Glecaprevir/Pibrentasvir Based on Real-World Use of Co-Medications in Patients with Chronic Hepatitis C Virus Infection: Data from the German Hepatitis C Registry (DHC-R). In HEPATOLOGY Vol. 68 (pp. 409A-410A). Retrieved from https://www.webofscience.com/

Conference Paper

2017

Impact of Comorbidities and Comedications on the Effectiveness of Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir ± Ribavirin in Clinical Practice: Real-World Evidence From a Multicountry Postmarketing Observational Study

Bourgeois, S., Curescu, M. G., Larrey, D. G., Marra, F., Dorr, P., Charafeddine, M., . . . Back, D. J. (2017). Impact of Comorbidities and Comedications on the Effectiveness of Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir ± Ribavirin in Clinical Practice: Real-World Evidence From a Multicountry Postmarketing Observational Study. In HEPATOLOGY Vol. 66 (pp. 852A). Retrieved from https://www.webofscience.com/

Conference Paper

Low rate of drug-drug interaction management during interferon-free simeprevir therapy - an integrated analysis of interventional and observational clinical studies

Marra, F., Siederdissen, C. H. Z., Khoo, S., Cornberg, M., Schlag, M., Ouwerkerk-Mahadevan, S., . . . Back, D. (2017). Low rate of drug-drug interaction management during interferon-free simeprevir therapy - an integrated analysis of interventional and observational clinical studies. In JOURNAL OF HEPATOLOGY Vol. 66 (pp. S314). Retrieved from https://www.webofscience.com/

Conference Paper

Partial directly observed therapy with ombitasvir/paritaprevir based regimens allows for successful treatment of patients on daily supervised methadone

Boyle, A., Marra, F., Fox, R., Morris, J., Fleming, C., Reilly, E., . . . Barclay, S. T. (2017). Partial directly observed therapy with ombitasvir/paritaprevir based regimens allows for successful treatment of patients on daily supervised methadone. In JOURNAL OF HEPATOLOGY Vol. 66 (pp. S282). doi:10.1016/S0168-8278(17)30881-4

DOI
10.1016/S0168-8278(17)30881-4
Conference Paper

Successful management of drug interactions with ritonavir-containing hepatitis C virus regimens in routine clinical practice

Marra, F., Boyle, A., Fox, R., Fleming, C., Reilly, E., Heydtmann, M., . . . Barclay, S. T. (2017). Successful management of drug interactions with ritonavir-containing hepatitis C virus regimens in routine clinical practice. In JOURNAL OF HEPATOLOGY Vol. 66 (pp. S314-S315). Retrieved from https://www.webofscience.com/

Conference Paper

2016

Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort

Siederdissen, C. H. Z., Maasoumy, B., Marra, F., Deterding, K., Port, K., Manns, M. P., . . . Wedemeyer, H. (2016). Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. CLINICAL INFECTIOUS DISEASES, 62(5), 561-567. doi:10.1093/cid/civ973

DOI
10.1093/cid/civ973
Journal article

2015

Drug-drug interactions with novel all oral interferon free antiviral agents - all issues solved?

Maasoumy, B., Siederdissen, C. H. Z., Marra, F., Deterding, K., Port, K., Manns, M. P., . . . Wedemeyer, H. (2015). Drug-drug interactions with novel all oral interferon free antiviral agents - all issues solved?. In JOURNAL OF VIRAL HEPATITIS Vol. 22 (pp. 89-90). doi:10.1111/jvh.129_12425

DOI
10.1111/jvh.129_12425
Conference Paper

CLINICAL SIGNIFICANCE OF DRUG-DRUG INTERACTIONS DURING THERAPY WITH NOVEL DAAS AGAINST HCV

Siederdissen, C. H. Z., Maasoumy, B., Marra, F., Deterding, K., Port, K., Manns, M. P., . . . Wedemeyer, H. (2015). CLINICAL SIGNIFICANCE OF DRUG-DRUG INTERACTIONS DURING THERAPY WITH NOVEL DAAS AGAINST HCV. In JOURNAL OF HEPATOLOGY Vol. 62 (pp. S612). Retrieved from https://www.webofscience.com/

Conference Paper

Co-morbidities and co-medications of patients with chronic hepatitis C (CHC) under specialist care in the UK - Challenges for scaling up HCV treatment?

Hudson, B. E., Irving, W., Barclay, S. T., Marra, F., & Walker, A. J. (2015). Co-morbidities and co-medications of patients with chronic hepatitis C (CHC) under specialist care in the UK - Challenges for scaling up HCV treatment?. In HEPATOLOGY Vol. 62 (pp. 772A). Retrieved from https://www.webofscience.com/

Conference Paper

High prevalence of co-morbidities and complex polypharmacy with drug-drug interaction (DDI) potential in patients with chronic Hepatitis C (CHC). Consistent findings from large primary care databases in the United Kingdom, Germany, and France

Marra, F., Leber, W., Barclay, S. T., Christensen, S., Ouzan, D., Oules, V., . . . Ansolabehere, X. (2015). High prevalence of co-morbidities and complex polypharmacy with drug-drug interaction (DDI) potential in patients with chronic Hepatitis C (CHC). Consistent findings from large primary care databases in the United Kingdom, Germany, and France. In HEPATOLOGY Vol. 62 (pp. 725A). Retrieved from https://www.webofscience.com/

Conference Paper

Prevalence of drug-drug interactions with modern interferon free antiviral regimens against hepatitis C in a large real-world cohort

Maasoumy, B., Siederdissen, C. H. Z., Marra, F., Port, K., Deterding, K., Manns, M. P., . . . Wedemeyer, H. (2015). Prevalence of drug-drug interactions with modern interferon free antiviral regimens against hepatitis C in a large real-world cohort. In HEPATOLOGY Vol. 62 (pp. 767A-768A). Retrieved from https://www.webofscience.com/

Conference Paper